Form 4: Elevance Health Executive Peter Haytaian Reports Stock Transactions

Elevance Health's EVP & President Carelon & CarelonRx, Peter D Haytaian, reports acquisition and disposal of company stock, including transactions related to option exercises and tax liability coverage.

Summary

• Peter D Haytaian, EVP & President Carelon & CarelonRx of Elevance Health, Inc., filed a Form 4 detailing changes in beneficial ownership of the company's stock.
• On March 1, 2024, Haytaian acquired 2,405 restricted share units and 9,152 performance-based restricted share units, both at $0.
• Also on March 1, 2024, 4,314 shares were withheld to cover tax liabilities at a price of $499.11.
• On March 4, 2024, Haytaian exercised options to acquire 15,000 shares at $166.97 per share.
• Haytaian also sold 4,206 shares, 1,889 shares, and 15,000 shares on March 4, 2024, at $500.18 per share, pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following these transactions, Haytaian directly owns 18,887 shares of Elevance Health common stock.
• Haytaian also acquired 9,280 employee stock options on March 1, 2024, exercisable starting March 1, 2025.
• After exercising options, Haytaian holds 4,908 employee stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are routine and don't necessarily indicate a strong positive or negative outlook. The sales are pre-planned, and the acquisitions are part of a standard compensation package.

Positives

• The acquisition of restricted share units and performance-based restricted share units indicates confidence in the company's future performance.
• The exercise of stock options suggests the executive believes the stock price will continue to rise.

Negatives

• The sale of shares, even under a pre-arranged trading plan, could be interpreted negatively by some investors, although it's a common practice for executives to diversify their holdings.

Risks

• Executive stock sales could create short-term downward pressure on the stock price.
• Changes in executive compensation structures, such as the vesting schedules of restricted stock units, could impact executive motivation and retention.

Future Outlook

The document does not contain explicit forward-looking statements, but the vesting schedules of restricted stock units and the exercisability of stock options suggest a long-term alignment of the executive's interests with the company's performance.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies like Elevance Health. Monitoring these transactions can provide insights into management's sentiment and confidence in the company's prospects, relative to peers such as UnitedHealth Group (UNH) or CVS Health (CVS).

Comparison to Industry Standards

• Executive compensation practices, including the use of stock options and restricted stock units, are standard across the healthcare industry.
• Companies like UnitedHealth Group and CVS Health also utilize similar equity-based compensation to align executive interests with shareholder value.
• The vesting schedules and exercise prices are generally in line with industry norms for executive compensation packages.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for short-term price fluctuations.
• Employees may be affected by the executive's actions, as they could be interpreted as a signal of confidence or lack thereof in the company's future.

Key Dates